Bcr-aBL1 kinase domain mutation analysis in chronic myeloid leukaemia patients with suboptimal response to tyrosine kinase inhibitors
Background: The acquired mutations in the BCR-ABL1 kinase domain (KD) may contribute to resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) patients. The aim of our work was to perform the BCRABL1 mutation analysis in a cohort of CML patients receiving TKIs, who did...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Slovenian Medical Association
2012-12-01
|
Series: | Zdravniški Vestnik |
Online Access: | http://vestnik.szd.si/index.php/ZdravVest/article/view/755 |